AlzeCure Pharma has presented new study results at at the Alzheimer’s Association International Conference (AAIC) 2021.
The new results demonstrate how their clinical candidate drug ACD856 for Alzheimer’s disease binds to neurotrophin receptors, so-called Trk receptors. The studies show that ACD856 affects important neurotransmitters in areas of the brain that play an important role in cognition and memory.
The possibilities to potentially treat several different disease states
The end result is the potent effect that ACD856 exhibits on cognition and memory ability in a number of preclinical models, states the company. The presentation also demonstrates the good safety profile that the substance shows and contains results from the first clinical study that ACD856 underwent during the first half of 2020. Overall, the data indicate that the substance is well suited for further clinical development.
“The results presented show the solid scientific package that forms the rational for the current clinical phase I study with ACD856 and the possibilities to potentially treat several different disease states, not just Alzheimer’s,” says Martin Jönsson, CEO of AlzeCure Pharma.